Goldman Sachs’s ChemoCentryx, Inc. CCXI Stock Holding History

Goldman Sachs’s Portfolio CCXI Stock Details CCXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-9,000	Closed	-$461K	–	6706
2021 Q1	$461K	Hold	9,000	–	–	﹤0.01%	5185
2020 Q4	$557K	Buy	+9,000	New	+$515K	﹤0.01%	4545
2020 Q3	–	Sell	-64,200	Closed	-$3.69M	–	5611
2020 Q2	$3.69M	Buy	64,200 +53,100	+478%	+$2.89M	﹤0.01%	3013
2020 Q1	$446K	Buy	+11,100	New	+$471K	﹤0.01%	4282
2013 Q4	–	Sell	-1,500	Closed	-$8K	–	6842
2013 Q3	$8K	Buy	+1,500	New	+$16.2K	﹤0.01%	6490

Other funds holding CCXI

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Goldman Sachs's CCXI Position: Q4 2022 in Review

Goldman Sachs sold out of ChemoCentryx, Inc. (CCXI) in Q4 2022, closing a stake of 5,616,301 shares — an estimated $290M sold.

Goldman Sachs first reported a position in CCXI in Q3 2013 and held it in 31 quarters. The position peaked at $290M in Q3 2022. 1 fund tracked by Wall St. Rank holds CCXI as of Q4 2022.

Goldman Sachs reported no remaining ChemoCentryx, Inc. position as of Q4 2022 after selling out during the quarter.
Goldman Sachs sold 5,616,301 ChemoCentryx, Inc. shares in Q4 2022, an estimated $290M.
Goldman Sachs first reported a position in ChemoCentryx, Inc. in Q3 2013 and held it in 31 quarters.
Goldman Sachs's ChemoCentryx, Inc. position peaked at $290M in Q3 2022.
1 fund tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2022.

Based on Goldman Sachs's 13F filing for Q4 2022, filed 13 Feb 2023.